aspigen inc.
Trade trend analysis
Mon
|
Year
Number of Transactions Quantity Weight
Number of Transactions Quantity Weight
The above chart presents the market trend analysis for aspigen inc. from 2025 to 2026. By examining various dimensions such as transaction quantity, transaction weight, average price, and transaction frequency, we can gain an intuitive understanding of the company's performance in terms of procurement cycles, business scale, and stability. As of 2026, the company has completed 15 transactions, with a transaction quantity of 4445.56 and a transaction weight of 4445.56.
- Year Transactions Quantity Weight
- 2025 30 11279.84 11279.84
- 2026 15 4445.56 4445.56
Bill of lading data
< 1/15 >- Trade date 2026/05/30 B/L No. 91003050625120
- Suppliers aspigen inc. Buyers next pharma sourcing s.a.s.
- POLs —— PODs bogota
- Supply area United States Purchas area Colombia
- Weight 219.61kg Amount 20904
- Hs code 3004902400 Product tags equipped with fixed dose drug
- Product description DO 902605491 001 PEDIDO TRAMITE OC 11323 2 HIDROXYUREA LOTES 25LHY03 25LHY04 DECLARACION(1 1) REGISTRO DE IMPORTACION Expand
- Trade date 2026/05/29 B/L No. 91003050619720
- Suppliers aspigen inc. Buyers next pharma sourcing s.a.s.
- POLs —— PODs bogota
- Supply area United States Purchas area Colombia
- Weight 130kg Amount 9568
- Hs code 3004902400 Product tags equipped with fixed dose drug
- Product description DO 902511479 001 PEDIDO TRAMITE OC 11350 GEMCIT SPAL P 1G DECLARACION(1 1) REGISTRO DE IMPORTACION REG 50080399 2026042 Expand
- Trade date 2026/05/28 B/L No. 91003050601483
- Suppliers aspigen inc. Buyers next pharma sourcing s.a.s.
- POLs —— PODs bogota
- Supply area United States Purchas area Colombia
- Weight 23.05kg Amount 42154
- Hs code 3004902400 Product tags equipped with fixed dose drug
- Product description CARMUSTINA DECLARACION(1 1) REGISTRO DE IMPORTACION REG 50095551 20260518N FECHA DE APROBACION 2026 05 18 FECHA DE VENCIMIENTO 2026 11 18 VISTO BUENO INVIMA VINVIMA 26 0069027 FECHA DE APROBACION 2026 05 18. FACTURA SPAL 26 27 E 008 FECHA 2026 04 11 (ITEM 1) CARM SPAL P 100 (CARMUSTINE POWDER FOR CONCENTRATE FOR SOLUTIONS FOR INFUSION USP (100MG VIAL) PRODUCTO CARM SPAL P 100 NOMBRE COMERCIAL CARMUSTINA 100 MG PRINCIPIO ACTIVO CADA VIAL DE POLVO LIOFILIZADO CONTIENE CARMUSTINA 100 MG CONCENTRACION CARMUSTINA 100MG VIAL INDICACIONES TERAPEUTICAS AGENTE ANTINEOPLASICO UNICO O COMBINADO EN TUMORES CEREBRALES MIELOMA MULTIPLE ENFERMEDAD DE HODGKIN Y LINFOMAS MELANOMA CANCER GASTROINTESTINAL. Expand
- Trade date 2026/05/27 B/L No. 91003050576999
- Suppliers aspigen inc. Buyers next pharma sourcing s.a.s.
- POLs —— PODs bogota
- Supply area United States Purchas area Colombia
- Weight 400.93kg Amount 30135.7
- Hs code 3004902400 Product tags equipped with fixed dose drug
- Product description PRIVATELIMITED DIRECION DEL FABRICANTE PLOT NO. 12 BIOTECH PARK PHASE II LALGADI MALAKPET MEDCHAL 500101 INDIA PAIS DE ORIGEN INDIA LOTE 26BME01 FECHA DE MANUFACTURA 02 26 FECHA DE EXPEDICION 01 28 CANT (225500) TABLETAS (ITEM 3) SPTREX 2.5MG(METHOTREXATE TABLETS2.5 MG USP) PRODUCTO SPTREX 2.5 TABLETAS NOMBRE COMERCIAL SPTREX 2.5 TABLETAS PRINCIPIO ACTIVO METOTREXATO CONCENTRACION 2.5 MG INDICACIONES TERAPEUTICAS COADYUVANTE EN EL TRATAMIENTO DE TUMORES DE TROFOBLASTO CORIOCARCINOMA YMOLA HIDITADIFORME YEN EL TRATAMIENTO DE LA LEUCEMIA LINFOCITICA AGUDA LINFOSARCOMA Y PSORIASIS. ARTRITIS REUMATOIDE INCLUYENDO ARTRITIS REUMATOIDE JUVENIL (JRA) DE Expand
- Trade date 2026/04/13 B/L No. 92003007069731
- Suppliers aspigen inc. Buyers next pharma sourcing s.a.s.
- POLs —— PODs bogota
- Supply area United States Purchas area Colombia
- Weight 1165.92kg Amount 653846.83
- Hs code 3002122100 Product tags antisera,blood fractions
- Product description DO 902604166-001 PEDIDO TRAMITE: OC 11296-2 INMUNOREL LOTE ID05G25100 DECLARACION(1-1) REGISTRO DE IMPORTACION: REG-5001 Expand
- Trade date 2026/03/31 B/L No. 07171260162981
- Suppliers aspigen inc. Buyers next pharma sourcing s.a.s.
- POLs —— PODs bogota
- Supply area United States Purchas area Colombia
- Weight 160.76kg Amount 14296
- Hs code 3004902400 Product tags equipped with fixed dose drug
- Product description DO 902603046-001 PEDIDO TRAMITE: OC 1132 HIDROXIUREA LOTE 25LHY02, 25LHY03, 25LHY04 DECLARACION(1-1) REGISTRO DE IMPORTA Expand
- Trade date 2026/03/24 B/L No. 91003049616803
- Suppliers aspigen inc. Buyers next pharma sourcing s.a.s.
- POLs —— PODs bogota
- Supply area United States Purchas area Colombia
- Weight 80.15kg Amount 124047
- Hs code 3004902400 Product tags equipped with fixed dose drug
- Product description DO 902603297-001 PEDIDO TRAMITE: OC 11317-3 PALIT SPAL LOTE 26APP01 DECLARACION(1-1) REGISTRO DE IMPORTACION REG-50179359-20250925N.M01 FECHA DE APROBACION 2026-03-18 FECHA DE VENCIMIENTO: 2026-06-25, VISTO BUENO INVIMA: VINVIMA-26-0038093. FECHA DE APROBACION: 2026-03-17. FACTURA: SPAL/25-26/E/146 FECHA: 2026-02-02 (ITEM 1) PALIT SPAL 100 (PACLITAXEL PROTEIN BOUND PARTICLES FOR INJECTABLE SUSPENSION 100MG); PRODUCTO: PALIT SPAL 100, NOMBRE COMERCIAL: PALIT SPAL 100, PRINCIPIO ACTIVO: CADA VIAL CONTIENE POLVO LIOFILIZADO PARA RECONSTITUIR A SUSPENSION INYECTABLE PACLITAXEL 100 MG, CONCENTRACION: 100 MG, INDICACIONES TERAPEUTICAS: CANCER DE MAMA METASTUSICO PACLITAXEL LIGADO A ALBUMINA ESTA INDICADO PARA TRATAR EL CANCER DE MAMA EN CASO DE FRACASAR LA QUIMIOTERAPIA COMBINADA PARA LA ENFERMEDAD METASTUSICA O LA RECIDIVA DENTRO DE LOS 6 MESES DE QUIMIOTERAPIA ADYUVANTE. EL TRATAMIENTO PREVIO DEBE HABER INCLUIDO UNA ANTRACICLINA, A MENOS QUE ¿STA ESTA CLUNICAMENTE CONTRAINDICADA. CANCER DE PULMIN NO MICROC¿TICO Expand
- Trade date 2026/03/02 B/L No. 91003049284704
- Suppliers aspigen inc. Buyers next pharma sourcing s.a.s.
- POLs —— PODs bogota
- Supply area United States Purchas area Colombia
- Weight 24.79kg Amount 11892
- Hs code 3004902400 Product tags equipped with fixed dose drug
- Product description DO 902602497-001 PEDIDO TRAMITE: OC 11316 MELFALAN LOTE 25LMP01 + OC 11317-1 PALIT SPAL LOTE 26APP01 DECLARACION(1-2) REGISTRO DE IMPORTACION REG-50204480-20251030N FECHA DE APROBACION 2025-10-30, FECHA DE VENCIMIENTO 2026-04-30, VISTO BUENO INVIMA VINVIMA-25-0151301 FECHA DE APROBACION 2025-10-30. FACTURA: SPAL/25-26/E/151 FECHA: 2026-02-14 (ITEM 1) MELP SPAL - 50 (MELPHALAN POWDER FOR SOLUTION FOR INJECTION/INFUSION BP 50MG/VIAL); PRODUCTO: MELFALAN, NOMBRE COMERCIAL: MELP SPAL POLVO LIOFILIZADO PARA RECONSTITUIR A SOLUCION INYECTABLE, PRINCIPIO ACTIVO: CADA VIAL CONTIENE MELFALAN CLORHIDRATO, EQUIVALENTE A MELFALAN 50 MG, CONCENTRACION: MELFALAN 50 MG/ML, INDICACIONES TERAPEUTICAS: TRATAMIENTO DEL MIELOMA, Y DEL ADENOCARCINOMA OV¿RICO AVANZADO, CARCINOMA AVANZADO DE MAMA, MELANOMA MALIGNO Y SARCOMA LOCALIZADO EN TEJIDO BLANDO, FORMA FARMACEUTICA: POLVO LIOFILIZADO, TIPO DE EMPAQUE: CAJA X 1 VIAL DE VIDRIO TRANSPARENTE TIPO I CON TAPON DE CAUCHO DE BROMOBUTILO GRIS Y TAPA TIPO FLIP OFF GRIS Y 1 VIAL DEVIDR Expand
- Trade date 2026/03/02 B/L No. 91003049284808
- Suppliers aspigen inc. Buyers next pharma sourcing s.a.s.
- POLs —— PODs bogota
- Supply area United States Purchas area Colombia
- Weight 6.22kg Amount 10000
- Hs code 3004902400 Product tags equipped with fixed dose drug
- Product description DO 902602497-001 PEDIDO TRAMITE: OC 11316 MELFALAN LOTE 25LMP01 + OC 11317-1 PALIT SPAL LOTE 26APP01 DECLARACION(2-2) SE PRESENTA LEGALIZACION VOLUNTARIA SIN PAGO DE SANCION POR MERCANCIA NO AMPARADA EN EL DOCUMENTO DE TRANSPORTE, DE ACUERDO CON LO ESTABLECIDO EN EL ARTICULO 52 PARAGRAFO 4, ARTICULO 290 NUMERAL 4, DEL DECRETO 1165 DE 2019. REGISTRO DE IMPORTACION REG-50195934-20251020N FECHA DE APROBACION 2025-10-20, FECHA DE VENCIMIENTO 2026-04-20, VISTO BUENO INVIMA VINVIMA-25-0145356 FECHA DE APROBACION 2025-10-20. FACTURA: SPAL/25-26/E/151 FECHA: 2026-02-14 (ITEM 2) PALIT SPAL 100 (PACLITAXEL PROTEIN BOUND PARTICLES FOR INJECTABLE SUSPENSION 100MG); PRODUCTO: PACLITAXEL 100 MG/ 16.7 ML SOLUCION INYECTABLE CONCENTRADA PARA INFUSION, NOMBRE COMERCIAL: PACLITAXEL 100 MG, PRINCIPIO ACTIVO: PACLITAXEL SOLUCION INYECTABLE 100 MG, CONCENTRACION: 100 MG, INDICACIONES TERAPEUTICAS: CANCER DE OVARIO: EN QUIMIOTERAPIA DE PRIMERA LINEA DE CANCER DE OVARIO, PACLITAXEL ESTA INDICADO PARA EL TRATAMIENTO DE PACIENTESCON Expand
- Trade date 2026/02/26 B/L No. 92003005827359
- Suppliers aspigen inc. Buyers next pharma sourcing s.a.s.
- POLs —— PODs bogota
- Supply area United States Purchas area Colombia
- Weight 1923.84kg Amount 1091458.56
- Hs code 3002122100 Product tags antisera,blood fractions
- Product description DO 902601193-001 PEDIDO TRAMITE: OC 11296 INMUNOREL LOTE ID05G25082, ID05G25100 - OC 11297 INMUNOREL 10% LOTE ID10F25003 DECLARACION(1-2) REGISTRO DE IMPORTACION REG-50012337-20260121N FECHA DE APROBACION 2026-01-21 FECHA DE VENCIMIENTO 2026-07-21, VISTOBUENO INVIMA VINVIMA-26-0008887 FECHA DE APROBACION 2026-01-21.. FACTURA: 4059604911 FECHA: 2026-01-29 (ITEM 2) MEDICAMENTO VITAL NO DISPONIBLE, HUMAN NORMAL IMMUNOGLOBULIN FOR INTRAVENOUS ADMINISTRATION B.P. 5% SOLUTION 100 ML,; PRODUCTO: INMUNOGLOBULINAHUMANA NORMAL 5% (50 MG/ML) SOLUCION INYECTABLE (IMMUNOREL), ORIGEN: SANGRE HUMANA, ASPECTO FISICO: LIQUIDO, SOLUCION INYECTABLE, TIPO DE EMPAQUE: CAJA X 1 VIAL, CADA VIAL POR 100 ML, USO: HUMANO, MARCA: IMMUNOREL, NUMERO DEL AUTORIZACION INVIMA DE LA SOLICITUD DE AUTORIZACION: 20251396131,, FECHA DE AUTORIZACION: 31/12/2025, CODIGO IUM: 1I1030991005100, TIEMPO DEL TRATAMIENTO INDICADO EN LA AUTORIZACION: NO APLICA NOMBRE DEL LABORATORIO FABRICANTE: RELIANCE LIFE SCIENCES PVT. LTD., UBICADO EN DHIRUBHAIAMBANI Expand
- Trade date 2026/02/26 B/L No. 92003005827366
- Suppliers aspigen inc. Buyers next pharma sourcing s.a.s.
- POLs —— PODs bogota
- Supply area United States Purchas area Colombia
- Weight 140kg Amount 153600
- Hs code 3002122100 Product tags antisera,blood fractions
- Product description DO 902601193-001 PEDIDO TRAMITE: OC 11296 INMUNOREL LOTE ID05G25082, ID05G25100 - OC 11297 INMUNOREL 10% LOTE ID10F25003 DECLARACION(2-2) REGISTRO DE IMPORTACION REG-50009764-20260119N FECHA DE APROBACION 2026-01-19 FECHA DE VENCIMIENTO 2026-07-19, VISTOBUENO INVIMA VINVIMA-26-0007183 FECHA DE APROBACION 2026-01-19. FACTURA: 4059605236 FECHA: 2026-02-02 (ITEM 1) MEDICAMENTO VITAL NO DISPONIBLE, HUMAN NORMALIMMONOGLOBULIN FOR INTRAVENOUS ADMINISTRATION B.P. 10% SOLUTION 50 ML. PRODUCTO: INMUNOGLOBULINA 10% (100 MG/ML) SOLUCION PARA INFUSION (IMMUNOREL), ORIGEN: SANGRE HUMANA, ASPECTO FISICO: LIQUIDO, ES UNA SOLUCION, TIPO DE EMPAQUE: CAJA X 1 VIAL, CADA VIAL POR 50 ML, USO: HUMANO, MARCA: IMMUNOREL, IUM: 1I1033751003100, CON RADICACION DEL INVIMA NO. 20261000231 DEL 02-01-2026, FABRICANTE: RELIANCE LIFE SCIENCES PVT. LTD., UBICADO EN DHIRUBHAI AMBANI LIFE SCIENCES CENTRE, PLANT 4A, 4B, 4C 4D & 4E, R-282, TTC AREA OF MIDC, THANE BELAPUR ROAD, RABALE, NAVI MUMBAI THANE- 400701, MAHARASHTRA STATE, INDIA, AUTORIZ Expand
- Trade date 2026/02/24 B/L No. 91003049188940
- Suppliers aspigen inc. Buyers next pharma sourcing s.a.s.
- POLs —— PODs bogota
- Supply area United States Purchas area Colombia
- Weight 1.1kg Amount 2210
- Hs code 3004902400 Product tags equipped with fixed dose drug
- Product description DO 902602498-001 PEDIDO TRAMITE: OC 11317-2 PALIT SPAL LOTE 26APP01 DECLARACION(1-1) REGISTRO DE IMPORTACION REG-5019593 Expand
- Trade date 2026/01/28 B/L No. 91003048807939
- Suppliers aspigen inc. Buyers next pharma sourcing s.a.s.
- POLs —— PODs bogota
- Supply area United States Purchas area Colombia
- Weight 23.05kg Amount 40983.45
- Hs code 3004902400 Product tags equipped with fixed dose drug
- Product description DO 902601663-001 PEDIDO TRAMITE: OC 11310 CARMUSTINA LOTE 25JCR01 DECLARACION(1-1) REGISTRO DE IMPORTACION REG-50196942- Expand
- Trade date 2026/01/21 B/L No. 92003004787671
- Suppliers aspigen inc. Buyers next pharma sourcing s.a.s.
- POLs —— PODs bogota
- Supply area United States Purchas area Colombia
- Weight 127.2kg Amount 10392
- Hs code 3004902400 Product tags equipped with fixed dose drug
- Product description DO 902512534-001 PEDIDO TRAMITE: OC 11294 HYDROXYUREA LOTE 25HHY04 DECLARACION(1-1) REGISTRO DE IMPORTACION REG-50245506 Expand
- Trade date 2026/01/15 B/L No. 91003048591283
- Suppliers aspigen inc. Buyers next pharma sourcing s.a.s.
- POLs —— PODs bogota
- Supply area United States Purchas area Colombia
- Weight 18.94kg Amount 8592
- Hs code 3004902400 Product tags equipped with fixed dose drug
- Product description DO 902510556-001 PEDIDO TRAMITE: OC 11261 MELFALAN DECLARACION(1-1) REGISTRO DE IMPORTACION REG-50204480-20251030N FECHA Expand
Partners
Total 1- Rank Company Transactions Per Detail
- 1 next pharma sourcing s.a.s. colombiabuyer,they trade on 2026-05-30 89 92.71% >
Products
Total 5- Products Transactions Per Detail
-
equipped with fixed dose drug
6 46.15% > -
antisera
4 30.77% > -
blood fractions
4 30.77% > -
anesthetic
2 15.38% > -
drug
2 15.38% >
Hscode rank
Total 5- HSCode Name Transactions Per Detail
- HS 3004902400 6 46.15% >
- HS 3002122100 4 30.77% >
- HS 3004902100 2 15.38% >
- HS 3002419000 1 7.69% >
Trading Area
Total 1- Area Transactions Per Detail
- colombia 89 92.71% >
aspigen inc. is International Buyer&Supplier,
and primarily engages in the import and export business of products such as equipped with fixed dose drug，antisera，blood fractions.
According to the 52wmb.com global trade database, as of 2026-05-30, the company has completed 96 international trades,
with its main trading regions covering colombia etc.
The core products include HS3004902400，HS3002122100，HS3004902100 etc,
and its main trading partners are next pharma sourcing s.a.s..
These trade data are sourced from various countries' customs and public channels, and have undergone standardization and structuring processing.
They can reflect the import and export trends and main market layout of the enterprise, and are suitable for market trend analysis, competitor research, port transportation planning, supply chain optimization, and international customer development.
They provide reliable support for cross-border trade decision-making.
The trade data displayed on aspigen inc. is sourced from the 52wmb.com global trade database. It is based on legal records from customs and related public channels of various countries, and has been formatted and organized for user query and analysis.
We maintain compliance with the source and processing of data to ensure the objectivity of information, but due to the dynamic changes in international trade activities, some data may be delayed or changed.
Reference contact info
Email Hunting Tool